Listed

InterDigital, Inc.: Form 10-Q for the period ended Jun 30, 2021

Filed with the SEC on Aug 5, 2021 and accepted by EDGAR at Aug 5, 2021, 08:34 ET.

Share

Management's discussion and analysis

As filed, 38,145 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

OVERVIEW

The following discussion should be read in conjunction with the unaudited, condensed consolidated financial statements and notes thereto contained in Part I, Item 1 of this Quarterly Report on Form 10-Q, in addition to our 2020 Form 10-K, other reports filed with the SEC and the Statement Pursuant to the Private Securities Litigation Reform Act of 1995 — Forward-Looking Statements below.

Throughout the following discussion and elsewhere in this Form 10-Q, we refer to “recurring revenues” and “non-recurring revenues.” Recurring revenues are comprised of “current patent royalties” and “current technology solutions revenue.” Non-recurring revenues are comprised of “non-current patent royalties,” which include past patent royalties and royalties from static agreements, as well as “patent sales.”

Throughout the following discussion and elsewhere in this Form 10-Q, we refer to the R&I Acquisition, in which we acquired Technicolor's R&I team. Refer to Note 5, "Business Combinations and Other Transactions," within the notes to the consolidated financial statements included in Part II, Item 8 of the 2020 Form 10-K for further information on the Technicolor transactions.

Xiaomi Patent License Agreement

On August 3, 2021, we announced that we have entered into a multi-year, worldwide, non-exclusive, royalty bearing license with a subsidiary of Xiaomi. The license covers Xiaomi’s cellular-enabled mobile devices under our standard essential patents related to cellular wireless (including 3G, 4G and 5G), WiFi and HEVC video technology. As part of the agreement, we and Xiaomi have agreed to terminate all pending patent litigation and other proceedings between the companies. Second quarter 2021 revenue did not include any impact from the Xiaomi agreement, which was executed in third quarter 2021. We expect to recognize recurring and non-recurring revenue from this agreement, beginning in third quarter 2021, along with additional expenses to adjust our performance-based compensation accruals.

Recurring Revenue

Second quarter 2021 recurring revenue was $78.1 million, compared to recurring revenue of $85.2 million in second quarter 2020, an 8% year-over-year decrease. The decrease in fixed-fee royalty revenue was primarily due to a reduction from the expired LG patent license agreement, partially offset by additional revenues from eight new patent license agreements signed in the last twelve months. In April 2021, LG confirmed that it is exiting the smartphone market. Refer to "Results of Operations --Second Quarter 2021 Compared to Second Quarter 2020" for further discussion of our 2021 revenue.

Restructuring Activities

On June 10, 2021, we announced that, as a result of a strategic review of our research and innovation priorities, we commenced the process of a collective economic layoff in which we proposed a reduction in force of 66 employees in our research and innovation unit, 60 of whom are based in France. We have launched an information-consultation process with respect to the contemplated reorganization with the works council of certain of our French subsidiaries, as required by French law. We anticipate the reduction in force being finalized in 2021. Additionally, Chordant has begun the process of ceasing operations. The Company implemented a reduction in workforce action in second quarter 2021, consisting of 18 employees.

During second quarter 2021, we recognized $13.2 million restructuring expenses including $11.1 million severance and other benefits, an $11.0 million impairment on our patents and $1.2 million outside services and other associated costs, offset by a $10.0 million reimbursement agreement, which are included within “Restructuring Activities” in the condensed consolidated statement of income. Any remaining restructuring expenses are expected to be recognized in 2021.

We expect to recognize additional restructuring charges of $15 million - $20 million in the second half of 2021. We expect these actions will drive annualized recurring expense savings of approximately $15 million beginning in fourth quarter 2021.

Impact of COVID-19 Pandemic

In March 2020, the World Health Organization categorized the novel coronavirus ("COVID-19") as a pandemic, and it continues to significantly impact the United States and the rest of the world. Though the COVID-19 pandemic and the measures taken to reduce its transmission, such as the imposition of social distancing and orders to work-from-home and shelter-in-place, have altered our business environment and overall working conditions, we continue to believe that our strategic strengths, including talent, our strong balance sheet, stable revenue base, and the strength of our patent portfolio, will allow us to weather a rapidly changing marketplace.

While the environment in which we conduct our business and our overall working conditions have changed as a result of the COVID-19 pandemic, we experienced a limited impact on our operations and financial position during three months ended June 30, 2021. As discussed in our 2020 Form 10-K, fixed-fee royalties accounted for nearly 89% of our revenues in 2020. To that end, in the six months ended June 30, 2021, we did not experience a significant impact on our revenue due to COVID-19. Meanwhile, we have taken steps to protect the health and safety of our employees and their families, with our entire worldwide workforce continuing to work remotely with limited exceptions. We are currently planning for a return to in-person work as early as September 2021, however we continue to evaluate feasibility of this date based on the evolving environment and regulatory guidance. Most of our locations are open on a limited and voluntary basis as of July 1, 2021. Despite the remote working conditions, our business activities have continued to operate with minimal interruption, and we expect them to continue to operate efficiently. Although we have resumed work-related travel on a limited basis, we have conducted the majority of our licensing negotiations, investor presentations and participation in standards organizations and industry events virtually. Between March 12, 2020, when we began to work almost entirely remotely, and June 30, 2021, we successfully concluded ten new patent license agreements that we estimate will result in aggregate revenues exceeding $200.0 million over the terms of those agreements. Our financial position remains strong, we believe we have sufficient access to capital if needed, and we remain committed to our efforts around cost discipline.

Despite our success thus far in navigating the challenging environment that COVID-19 has presented, as more fully discussed in Part II, Item 1A "Risk Factors" in this Quarterly Report on Form 10-Q, the extent to which COVID-19 will adversely impact our business, financial condition and results of operations is dependent upon numerous factors resulting therefrom, many of which are highly uncertain, rapidly changing and uncontrollable. However, with a strong balance sheet and the vast majority of our current revenue coming from fixed price agreements, we believe that we are well-positioned to continue to overcome and adapt to the challenges that we have been presented with thus far.

Share Repurchase Program

During second quarter 2021, we repurchased 0.1 million shares for $5.4 million under the 2014 Repurchase Program. As of June 30, 2021, there was approximately $60.3 million remaining under the stock repurchase authorization. In the period July 1, 2021 through August 3, 2021, we repurchased 0.1 million shares for $8.8 million under the 2014 Repurchase Program.

Comparability of Financial Results

When comparing second quarter 2021 financial results against other periods, the following items should be taken into consideration:

  • Our second quarter 2021 revenue includes $9.6 million of non-recurring revenue primarily related to a static fixed-fee patent licensing agreement signed in second quarter 2021.
  • During second quarter 2021, we recognized $13.2 million restructuring expenses including $11.1 million severance and other benefits, an $11.0 million impairment on our patents and $1.2 million outside services and other associated costs, offset by a $10.0 million reimbursement agreement. These costs resulted from our restructuring activities as described in Note 11, "Restructuring Activities", within the notes to condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, and are included within “Restructuring activities” expenses in the condensed consolidated statement of income. The patents held for sale are recorded at fair value on June 30, 2021 and are included within "Prepaid and other current assets" in the consolidated balance sheet.
  • During second quarter 2021, we incurred $2.0 million of additional non-recurring personnel-related costs expenses related to new employee agreements.
  • Interest expense decreased in second quarter 2021 by $3.3 million primarily due to a reduction in non-cash interest expense resulting from the accounting adoption of ASU 2020-06, related to the accounting for convertible debts.
  • In second quarter 2021 we recognized a $1.0 million gain resulting from observable price changes of one of our long-term strategic investments, which was included within “Other Income, Net” in the condensed consolidated statement of income.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our significant accounting policies are described in Note 2, "Summary of Significant Accounting Policies and New Accounting Guidance", in the notes to consolidated financial statements included in our 2020 Form 10-K. A discussion of our critical accounting policies, and the estimates related to them, are included in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2020 Form 10-K. There have been no material changes to our existing critical accounting policies from the disclosures included in our 2020 Form 10-K. In addition, we have analyzed the impact of COVID-19 on our financial statements as of June 30, 2021, and we have determined that the changes to our significant judgments and estimates did not have a material impact on our financial statements. Refer to Note 1, “Basis of Presentation,” in the notes to condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for updates related to new accounting pronouncements and changes in accounting policies.

FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES

Our primary sources of liquidity are cash, cash equivalents and short-term investments, as well as cash generated from operations. We believe we have the ability to obtain additional liquidity through debt and equity financings. Based on our past performance and current expectations, we believe our available sources of funds, including cash, cash equivalents and short-term investments and cash generated from our operations, will be sufficient to finance our operations, capital requirements, debt obligations, existing stock repurchase program and dividend program for the next twelve months.

Cash, cash equivalents, restricted cash and short-term investments

As of June 30, 2021 and December 31, 2020, we had the following amounts of cash, cash equivalents, restricted cash and short-term investments (in thousands):

June 30, 2021 December 31, 2020 Increase / (Decrease)
Cash and cash equivalents $410,144 $473,474 $(63,330)
Restricted cash included within prepaid and other current assets 741 3,108 (2,367)
Restricted cash included within other non-current assets 1,081 1,081 —
Short-term investments 425,759 453,173 (27,414)
Total cash, cash equivalents, restricted cash and short-term investments $837,725 $930,836 $(93,111)

The net decrease in cash, cash equivalents, restricted cash and short-term investments was attributable to cash used in financing activities of $33.1 million, primarily related to dividend payments and repurchases of common stock, cash used in investing activities of $22.3 million, excluding sales and purchases of short-term investments, and cash used in operating activities of $37.1 million. Refer to the sections below for further discussion of these items.

Cash flows from operating activities

We used the following cash flows in our operating activities in first half 2021 and 2020 (in thousands):

Six months ended June 30, 2021 2020 Increase / (Decrease)
Net cash provided by (used in) operating activities $(37,101) $42,870 $(79,971)

26

Our cash flows provided by (used in) operating activities are principally derived from cash receipts from patent license and technology solutions agreements, offset by cash operating expenses and income tax payments. The $80.0 million change in net cash used in operating activities was primarily driven by lower cash receipts, primarily related to new patent license agreements signed over the last twelve months, as well as the timing of cash receipts related to existing patent license agreements. The table below sets forth the significant items comprising our cash flows provided by (used in) operating activities during the six months ended June 30, 2021 and 2020 (in thousands):

Cash Receipts: Six months ended June 30, 2021 2020 Increase / (Decrease)
Patent royalties $75,435 $155,330 $(79,895)
Technology solutions 3,412 3,403 9
Total cash receipts 78,847 158,733 (79,886)
Cash Outflows:
Cash operating expenses a 105,729 97,159 8,570
Income taxes paid b 4,793 13,788 (8,995)
Total cash outflows 110,522 110,947 (425)
Other working capital adjustments (5,426) (4,916) (510)
Cash flows (used in) provided by operating activities $(37,101) $42,870 $(79,971)

(a) Cash operating expenses include operating expenses less depreciation of fixed assets, amortization of patents, non-cash compensation and non-cash changes in fair value.

(b) Income taxes paid include foreign withholding taxes.

Cash flows from investing and financing activities

Net cash provided by in investing activities in first half 2021 was $4.5 million, a $10.7 million change from $6.2 million of net cash used in investing activities in first half 2020. During first half 2021, we sold $26.7 million of short-term marketable securities, net of purchases, we capitalized $21.2 million of patent costs and property plant and equipment purchases, and invested $1.1 million in a new strategic investment. During first half 2020, we sold $11.4 million of short-term marketable securities, net of purchases, and we capitalized $17.6 million of patent costs and property plant and equipment purchases.

Net cash used in financing activities for first half 2021 was $33.1 million, a change of $83.4 million from net cash used in financing activities of $116.5 million for first half 2020. This change was primarily attributable to a $94.9 million payment on long-term debt related to the repayment of our 2020 Notes during the first quarter 2020 offset by $10.8 million of additional repurchases of common stock and a $1.1 million non-controlling interest distribution in first quarter 2021.

Other

Our combined short-term and long-term deferred revenue balance as of June 30, 2021 was approximately $241.3 million, a net decrease of $86.7 million from December 31, 2020. This decrease in deferred revenue was primarily attributable to timing of cash receipts from our dynamic fixed-fee royalty agreements and amortization of deferred revenue recognized in the period.

Based on current license agreements, we expect the amortization of dynamic fixed-fee royalty payments to reduce the June 30, 2021 deferred revenue balance of $241.3 million by $158.9 million over the next twelve months.

Convertible Notes

See Note 7, “Obligations” to the notes to condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for definitions of capitalized terms below.

Our 2024 Notes, which for purposes of this discussion are also referred to as the "Convertible Notes", are included in the dilutive earnings per share calculation using the if-converted method, as required by the adoption of ASU 2020-06. Under the if-converted method, we must assume that conversion of convertible securities occurs at the beginning of the reporting period. As of December 31, 2020, we made the irrevocable election to settle all conversions of the 2024 Notes through combination settlements of cash and shares of our common stock, with a specified dollar amount of $1,000 per $1,000 principal amount of 2024 Notes and any remaining amounts in shares of common stock. As the principal amount must be paid in cash and only the conversion spread is settled in shares, we only include the net number of incremental shares that would be issued upon conversion. We must calculate the number of shares of our common stock issuable under the terms of the Convertible Notes based on the average market price of our common stock during the applicable reporting period and include that number in the total diluted shares figure for the period.

At the time we issued the Convertible Notes, we entered into the 2024 Call Spread Transactions that together were designed to have the economic effect of reducing the net number of shares that will be issued in the event of conversion of the Convertible Notes by, in effect, increasing the conversion price of the Convertible Notes from our economic standpoint. However, under GAAP, since the impact of the 2024 Note Hedge Transactions is anti-dilutive, we exclude from the calculation of fully diluted shares the number of shares of our common stock that we would receive from the counterparties to these agreements upon settlement.

During periods in which the average market price of our common stock is above the applicable conversion price of the Convertible Notes ($81.29 per share for the 2024 Notes as of June 30, 2021) or above the strike price of the warrants ($109.43 per share for the 2024 Warrant Transactions as of June 30, 2021), the impact of conversion or exercise, as applicable, would be dilutive and such dilutive effect is reflected in diluted earnings per share. As a result, in periods where the average market price of our common stock is above the conversion price or strike price, as applicable, under the if-converted method, we calculate the number of shares issuable under the terms of the Convertible Notes and the warrants based on the average market price of the stock during the period, and include that number in the total diluted shares outstanding for the period.

Under the if-converted method, changes in the price per share of our common stock can have a significant impact on the number of shares that we must include in the fully diluted earnings per share calculation. As described in Note 7, "Obligations," we made the irrevocable election to settle all conversions of the 2024 Notes through combination settlements of cash and shares of our common stock, with a specified dollar amount of $1,000 per $1,000 principal amount of 2024 Notes and any remaining amounts in shares of our common stock ("net share settlement"). Assuming net share settlement upon conversion, the following table illustrates how, based on the $400.0 million aggregate principal amount of the 2024 Notes outstanding as of June 30, 2021, and the approximately 4.9 million warrants related to the 2024 Notes outstanding as of the same date, changes in our stock price would affect (i) the number of shares issuable upon conversion of the Convertible Notes, (ii) the number of shares issuable upon exercise of the warrants subject to the 2024 Warrant Transactions, (iii) the number of additional shares deemed outstanding with respect to the Convertible Notes, after applying the if-converted method, for purposes of calculating diluted earnings per share ("Total If-Converted Method Incremental Shares"), (iv) the number of shares of our common stock deliverable to us upon settlement of the 2024 Note Hedge Transactions and (v) the number of shares issuable upon concurrent conversion of the Convertible Notes, exercise of the warrants subject to the 2024 Warrant Transactions, and settlement of the 2024 Note Hedge Transactions:

2024 Notes

(Shares in thousands)

Market Price Per Share Shares Issuable Upon Conversion of the 2024 Notes Shares Issuable Upon Exercise of the 2024 Warrant Transactions Total If-Converted Method Incremental Shares Shares Deliverable to InterDigital upon Settlement of the 2024 Note Hedge Transactions Incremental Shares Issuable (a)
$85 215 — 215 (215) —
$90 476 — 476 (476) —
$95 710 — 710 (710) —
$100 921 — 921 (921) —
$105 1,111 — 1,111 (1,111) —
$110 1,284 25 1,309 (1,284) 25
$115 1,442 238 1,680 (1,442) 238
$120 1,587 433 2,020 (1,587) 433
$125 1,721 613 2,334 (1,721) 613
$130 1,844 779 2,623 (1,844) 779

(a) Represents incremental shares issuable upon concurrent conversion of convertible notes, exercise of warrants and settlement of the hedge agreements.

RESULTS OF OPERATIONS

Second Quarter 2021 Compared to Second Quarter 2020

Revenues

The following table compares second quarter 2021 revenues to second quarter 2020 revenues (in thousands):

Three months ended June 30, 2021 2020 Total Increase/(Decrease)
Variable patent royalty revenue $7,323 $4,597 $2,726 59%
Fixed-fee royalty revenue 69,296 77,338 (8,042) (10)%
Current patent royalties a 76,619 81,935 (5,316) (6)%
Non-current patent royalties b 9,586 19,249 (9,663) (50)%
Total patent royalties 86,205 101,184 (14,979) (15)%
Current technology solutions revenue a 1,530 3,314 (1,784) (54)%
Total revenue $87,735 $104,498 $(16,763) (16)%

a. Recurring revenues are comprised of current patent royalties, inclusive of Dynamic Fixed-Fee Agreement royalties, and current technology solutions revenue.

b. Non-recurring revenues are comprised of non-current patent royalties, which include past patent royalties and royalties from static agreements, as well as patent sales.

The $16.8 million decrease in total revenue was primarily due to a $7.1 million decrease in recurring revenue and a $9.7 million decrease in non-current patent royalties. The decrease in recurring revenue was primarily due to the expired LG patent license agreement, partially offset by additional revenues from eight new patent license agreements signed in the last twelve months. The decrease in non-current patent royalties was driven by past sales royalties recognized from the Huawei patent license agreement signed in second quarter 2020, partially offset by royalties recognized from a static fixed-fee patent license agreement signed in second quarter 2021.

In second quarter 2021 and second quarter 2020, 79% and 75% of our total revenue, respectively, was attributable to companies that individually accounted for 10% or more of our total revenue. In second quarter 2021 and second quarter 2020, the following companies accounted for 10% or more of our total revenue:

Three months ended June 30, 2021 2020
Apple 32% 27%
Samsung 22% 19%
Huawei 13% 29%
Kyocera 12% <10%

Operating Expenses

The following table summarizes the changes in operating expenses between second quarter 2021 and second quarter 2020 by category (in thousands):

Three months ended June 30, 2021 2020 Increase/(Decrease)
Patent administration and licensing $40,970 $38,695 $2,275 6%
Development 21,870 22,092 (222) (1)%
Selling, general and administrative 14,799 11,794 3,005 25%
Restructuring activities 13,245 — 13,245 100%
Total operating expenses $90,884 $72,581 $18,303 25%

Operating expenses increased to $90.9 million in second quarter 2021 from $72.6 million in second quarter 2020. The $18.3 million increase in total operating expenses was primarily due to changes in the following items (in thousands):

Increase/(Decrease)
Restructuring activities $13,245
Personnel-related costs 3,373
Intellectual property enforcement and non-patent litigation 1,113
Other 572
Total increase in operating expenses $18,303

The $18.3 million increase in operating expenses was primarily driven by $13.2 million of non-recurring restructuring costs incurred as part of our overall restructuring plan. In addition, there was a $3.4 million increase in personnel-related costs, primarily driven by new employment agreements, and a $1.1 million increase in intellectual property enforcement costs, primarily driven by the ongoing Lenovo and Xiaomi litigations.

Patent Administration and Licensing Expense: The $2.3 million increase in patent administration and licensing expense primarily resulted from the increase in the intellectual property enforcement discussed above, as well as higher patent maintenance costs.

Development Expense: Development expense was relatively flat as compared to second quarter 2020.

Selling, General and Administrative Expense: The $3.0 million increase in selling, general and administrative expense was primarily due to the increase in personnel-related costs discussed above.

Restructuring Activities: We incurred $13.2 million of restructuring expenses associated with our overall restructuring plan, as described in Note 11, "Restructuring Activities" within the notes to condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Non-Operating Expense

The following table compares second quarter 2021 non-operating expense to second quarter 2020 non-operating expense (in thousands):

Three months ended June 30, 2021 2020 Increase/(Decrease)
Interest expense $(6,666) $(9,971) $3,305 33%
Interest and investment income 446 1,342 (896) (67)%
Other income, net 2,593 2,447 146 6%
Total non-operating expense $(3,627) $(6,182) $2,555 41%

The change in non-operating expense between periods was driven by $3.3 million of reduced non-cash interest expense due to the removal of the accretion of the debt discount on the 2024 Notes resulting from the adoption of ASU 2020-06. Additionally, interest and investment income decreased $0.9 million in the three months ended June 30, 2021 due to reduced rates of return on our short-term investments.

Income taxes

In second quarter 2021 and 2020, we had an effective tax rate of (0.3)% and 20.0%, respectively. The effective tax rate in both periods was impacted by losses in certain jurisdictions where the Company presently has recorded a valuation allowance against the related tax benefit. Excluding this valuation allowance, our second quarter 2021 and 2020 effective tax rate would have been 26.3% and 12.2%, respectively.

First Half 2021 Compared to First Half 2020

Revenues

The following table compares first half 2021 revenues to first half 2020 revenues (in thousands):

Six months ended June 30, 2021 2020 Total Increase/(Decrease)
Variable patent royalty revenue $14,419 $10,543 $3,876 37%
Fixed-fee royalty revenue 138,592 143,685 (5,093) (4)%
Current patent royalties a 153,011 154,228 (1,217) (1)%
Non-current patent royalties b 13,367 19,954 (6,587) 33%
Total patent royalties 166,378 174,182 (7,804) (4)%
Current technology solutions revenue a 3,720 6,526 (2,806) (43)%
Total revenue $170,098 $180,708 $(10,610) (6)%

(a) Recurring revenues are comprised of current patent royalties, inclusive of Dynamic Fixed-Fee Agreement royalties, and current technology solutions revenue.

(b) Non-recurring revenues are comprised of non-current patent royalties, which include past patent royalties and royalties from static agreements, as well as patent sales.

The $10.6 million decrease in total revenue was primarily driven by a $4.0 million decrease in recurring revenue and a $6.6 million decrease in non-current patent royalties. The decrease in recurring royalty revenue was primarily due to the expired LG patent license agreement, and was partially offset by additional revenues from nine new patent license agreements signed in the last fifteen months, including the Huawei patent license agreement signed in second quarter 2020. The decrease in non-current patent royalties was driven by past sales royalties recognized from the Huawei patent license agreement signed in second quarter 2020, partially offset by royalties recognized from two patent license agreement signed in first half 2021.

In first half 2021 and first half 2020, 69% and 70% of our total revenue, respectively, was attributable to companies that individually accounted for 10% or more of our total revenue. In first half 2021 and first half 2020, the following companies accounted for 10% or more of our total revenue:

Six months ended June 30, 2021 2020
Apple 33% 31%
Samsung 23% 22%
Huawei 13% 17%

Operating Expenses

The following table summarizes the changes in operating expenses between first half 2021 and first half 2020 by category (in thousands):

Six months ended June 30, 2021 2020 Increase/(Decrease)
Patent administration and licensing $77,544 $78,803 $(1,259) (2)%
Development 44,453 40,910 3,543 9%
Selling, general and administrative 26,016 24,397 1,619 7%
Restructuring activities 13,245 — 13,245 100%
Total operating expenses $161,258 $144,110 $17,148 12%

32

Operating expenses increased 12% to $161.3 million in first half 2021 from $144.1 million in first half 2020. The $17.1 million increase in total operating expenses was primarily due to changes in the following items (in thousands):

Increase/(Decrease)
Restructuring activities $13,245
Personnel-related costs 5,626
Intellectual property enforcement and non-patent litigation 2,386
Patent maintenance (1,611)
Corporate initiatives (1,952)
Other (546)
Total increase in operating expenses $17,148

The $17.1 million increase in operating expenses was primarily driven by $13.2 million of non-recurring restructuring costs incurred as part of our overall restructuring plan. In addition, there was a $5.6 million increase in personnel-related costs, primarily driven by new employment agreements, and a $2.4 million increase in intellectual property enforcement costs, primarily driven by the ongoing Lenovo and Xiaomi litigations. These increases were offset by a $1.6 million decrease in patent maintenance costs due to the ongoing efforts to effectively manage our patent portfolio size and a $2.0 million decrease due to ongoing efforts to optimize our cost structure, including the closing of our San Diego office.

Patent Administration and Licensing Expense: The decrease in patent administration and licensing expense primarily resulted from the above-noted decrease in patent maintenance costs, slightly offset by an increase in intellectual property enforcement costs. Additionally, lower personnel-related costs contributed to the decrease.

Development Expense: The increase in development expense primarily resulted from the above-noted increase in personnel-related expenses.

Selling, General and Administrative Expense: The increase in selling, general and administrative expense primarily resulted from the above-noted increase in personnel-related costs, and was partially offset by the above-noted corporate initiatives.

Restructuring Activities: The Company incurred $13.2 million of restructuring expenses associated with the Company's overall restructuring plan, as described in Note 11, "Restructuring Activities" within the notes to condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

Non-Operating Expense

The following table compares first half 2021 non-operating expense to first half 2020 non-operating expense (in thousands):

Six months ended June 30, 2021 2020 Increase/(Decrease)
Interest expense $(13,656) $(20,516) $6,860 33%
Interest and investment income 999 4,219 (3,220) (76)%
Other income, net 2,764 5,593 (2,829) 51%
Total non-operating expense $(9,893) $(10,704) $811 8%

The change in non-operating expense between periods was primarily driven by a $5.5 million gain in 2020, resulting from observable price changes of one of our long-term strategic investments, $6.9 million of reduced non-cash interest expense due to the removal of the accretion of the debt discount on the 2024 Notes resulting from the adoption of ASU 2020-06, $1.0 million of reduced interest expense due to the repayment of the 2020 Notes in first quarter 2020, and a $1.9 million gain in first quarter 2021 on a contract termination. Additionally, Interest and investment income decreased $3.2 million in the six months ended June 30, 2021 due to reduced rates of return on our short-term investments.

Income taxes

In first half 2021 and 2020, we had an effective tax rate of (169.6)% and 26.9%, respectively. The effective tax rate in both periods was driven by losses in certain jurisdictions where the Company presently has recorded a valuation allowance against the related tax benefit. Excluding this valuation allowance, our first half 2021 and 2020 effective tax rate would have been 104.3% and 12.5%, respectively. In the first half of 2021 and 2020, we recorded a net discrete tax expense of $0.6 million and $0.3 million, respectively, primarily related to share-based compensation.

STATEMENT PURSUANT TO THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 — FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include certain information under the heading “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information regarding our current beliefs, plans and expectations, including without limitation the matters set forth below. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “forecast,” "believe," "could," "would," "should," "if," "may," "might," "future," "target," “goal,” "trend," "seek to," "will continue," "predict," "likely," "in the event," variations of any such words or similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements regarding:

  • Our expectations regarding the potential effects of new accounting standards on our financial position, results of operations or cash flows;
  • Our expectation that the amortization of dynamic fixed-fee royalty payments will reduce our June 30, 2021 deferred revenue balance over the next twelve months;
  • Our expectations with respect to revenue to be recognized based on contracts signed and committed Dynamic Fixed-Fee Agreement payments as of June 30, 2021;
  • Our expectations and estimations regarding the income tax effects, and the impact on the Company, of the 2017 Tax Cuts and Jobs Act, including our forecasted net benefit related to our income qualifying as FDII;
  • Our expectations with respect to anticipated tax refunds to be received from amending certain tax returns;
  • The timing, outcome and impact of, and plans, expectations and beliefs with respect to, our various litigation, regulatory, administrative and legislative matters;
  • Our belief that we have the ability to obtain additional liquidity through debt and equity financings;
  • Our expectations with respect to the impact of the restructuring activities on our financial statements and our business;
  • Our belief that our available sources of funds will be sufficient to finance our operations, capital requirements, debt obligations, existing stock repurchase program and dividend program for the next twelve months;
  • Our expectation that we will continue to pay dividends comparable to our quarterly $0.35 per share cash dividend in the future;
  • Our expectations regarding our customers’ ability to continue to pay fixed fee payments owed to us despite the ongoing COVID-19 pandemic; and
  • Our expectations regarding the potential effects of the ongoing COVID-19 pandemic on our business, financial position, results of operations and cash flows.

Forward-looking statements concerning our business, results of operations and financial condition are inherently subject to risks and uncertainties that could cause actual results, and actual events that occur, to differ materially from results contemplated by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties outlined in greater detail in Part I, Item 1A of our 2020 Form 10-K and Part II, Item 1A "Risk Factors" in this Quarterly Report on Form 10-Q. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.

Market risk

As filed, 132 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes in quantitative and qualitative market risk from the disclosures included in our 2020 Form 10-K.

Controls and procedures

As filed, 1,378 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s principal executive officer and principal financial officer, with the assistance of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2021, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 10,013 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Reference is made to Part I, Item 1A, “Risk Factors” included in our 2020 Form 10-K for information concerning risk factors, which should be read in conjunction with the factors set forth in the Statement Pursuant to the Private Securities Litigation Reform Act of 1995 -- Forward-Looking Statements in Part I, Item 2 of this Quarterly Report on Form 10-Q. Except as set forth below, there have been no material changes with respect to the risk factors disclosed in our 2020 Form 10-K. The risk factors set forth below update, and should be read together with, the risk factors in our 2020 Form 10-K. You should carefully consider such factors, which could materially affect our business, financial condition or future results. The risks described in this Quarterly Report on Form 10-Q and in the 2020 Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition and/or operating results.

Risks related to the implementation of our strategic review.

As described in Note 11, "Restructuring Activities" within the notes to condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, on June 10, 2021, we announced that, as a result of a strategic review of our research and innovation priorities, we commenced the process of a collective economic layoff in which we proposed a reduction in force of 66 employees in our research and innovation unit. This process has placed substantial demands on our management, which could lead to the diversion of management’s attention from other business priorities, and we expect these demands will continue. This announcement could also lead to unanticipated work stoppages, low employee morale, decreased productivity, and a failure to deliver under existing commitments to third parties for research services, which could harm our business. Further, the process to undertake the collective economic layoff, which is governed by French labor law, could take more time than anticipated, and the costs associated therewith could be significantly more than anticipated. As a result of these or any other factors, we could fail to realize the anticipated benefits associated with the strategic review, which could in turn materially harm our business, financial condition and operating results.

The extent to which the COVID-19 pandemic or any other potential future public health crises, pandemics or similar events will adversely impact our business, financial condition and results of operations is highly uncertain and cannot be predicted.

The COVID-19 pandemic has created significant worldwide uncertainty, volatility and economic disruption. The extent to which COVID-19 and any other potential future public health crises, pandemics or similar events will adversely impact our business, financial condition and results of operations is dependent upon numerous factors, many of which are highly uncertain, rapidly changing and uncontrollable. These factors include, but are not limited to: (i) the duration and scope of the pandemic; (ii) governmental, business and individual actions that have been and continue to be taken in response to the pandemic or other event, including travel restrictions, quarantines, social distancing, work-from-home and shelter-in-place orders and shut-downs; (iii) the impact on our customers, including those that are presently unlicensed, and other business partners; (iv) the impact on U.S. and global economies and the timing and rate of economic recovery; (v) potential adverse effects on the financial markets and access to capital; (vi) potential goodwill or other impairment charges; (vii) increased cybersecurity risks as a result of pervasive remote working conditions; (viii) our ability to effectively carry out our operations due to any adverse impacts on the health and safety of our employees and their families; (ix) the ability of our customers to timely satisfy their payment obligations to us; and (x) fluctuations in global shipments of handsets and consumer electronics devices. Furthermore, as a result of the COVID-19 pandemic, our employees have been required to work from for an extended period of time. The significant increase in remote working could exacerbate certain risks to our business, including an increased risk of cybersecurity events, improper dissemination of personal or confidential information and breakdowns in internal controls and processes. Further, as our employees begin to return to work in our physical locations, they may be exposed to COVID-19, and we may face claims by such employees or regulatory authorities that we have not provided adequate protection to our employees with respect to the spread of COVID-19 at our physical locations, which may affect our business, results of operations, and reputation.

Potential patent and litigation reform legislation, potential USPTO and international patent rule changes, potential legislation affecting mechanisms for patent enforcement and available remedies, and potential changes to the intellectual property rights (“IPR”) policies of worldwide standards bodies, as well as rulings in legal proceedings, may affect our investments in research and development and our strategies for patent prosecution, licensing and enforcement and could have a material adverse effect on our licensing business as well as our business as a whole.

Potential changes to certain U.S. and international patent laws, rules and regulations may occur in the future, some or all of which may affect our research and development investments, patent prosecution costs, the scope of future patent coverage we secure, the number of forums in which we can seek to enforce our patents, the remedies that we may be entitled to in patent litigation, and attorneys’ fees or other remedies that could be sought against us, and may require us to reevaluate and modify our research and development activities and patent prosecution, licensing and enforcement strategies. For example, President Biden recently issued an executive order which, among other things, proposed considering changes to the USPTO, DOJ and National Institute of Standards and Technology’s joint policy statement on remedies for SEPs subject to FRAND commitments. The European Commission has also initiated a process to review the EU’s IP policies, in particular as they relate to SEPs and FRAND. Any change as it relates to these matters could impact our ability to negotiate license agreements on favorable terms or at all, limit our potential legal remedies and materially impact our business. Further, legislation designed to reduce the jurisdiction and remedial authority of the USITC has periodically been introduced in Congress.

Any potential changes in the law, the IPR policies of standards bodies or other developments that reduce the number of forums available or the type of relief available in such forums (such as injunctive relief), restrict permissible licensing practices (such as our ability to license on a worldwide portfolio basis) or that otherwise cause us to seek alternative forums (such as arbitration or state court), would make it more difficult for us to enforce our patents, whether in adversarial proceedings or in negotiations. Because we have historically depended on the availability of certain forms of legal process to enforce our patents and obtain fair and adequate compensation for our investments in research and development and the unauthorized use of our intellectual property, developments that undermine our ability to do so could have a negative impact on future licensing efforts.

Rulings in our legal proceedings as well as those of third parties may affect our strategies for patent prosecution, licensing and enforcement. For example, in recent years, the USITC and U.S. courts, including the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit, have taken some actions that have been viewed as unfavorable to patentees, including us. Decisions that occur in the U.S. or in international forums may change the law applicable to various patent law issues, such as, for example, patentability, validity, claim construction, patent exhaustion, patent misuse, permissible licensing practices, available forums, and remedies such as damages and injunctive relief, in ways that are detrimental to the ability of patentees to enforce patents and obtain suitable relief

We continue to monitor and evaluate our strategies for prosecution, licensing and enforcement with regard to these developments; however, any resulting change in such strategies may have an adverse impact on our business and financial condition.

We regularly make strategic decisions about our patent portfolio. Although we seek to focus our operations in areas where we see the potential for growth and to divest assets where we see more limited opportunities, dispositions we decide to undertake may involve risks, and the anticipated benefits of such actions may not be realized.

From time to time, we intend to make strategic decisions about our patent portfolio, whether through a formal portfolio review or opportunistic dispositions. Cost savings expectations of any portfolio review are inherently uncertain and, therefore, we cannot provide assurance that we will achieve any expected, or any actual cost savings from any such action. Our portfolio review activities may place substantial demands on our management, which could lead to the diversion of management’s attention from other business priorities. We have divested a number of assets, including as part of a recent strategic portfolio rationalization review. Any assets that we divest could turn out to be more valuable than we had anticipated and we may not realize the anticipated benefits of any strategic decision about our patent portfolio.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-04-01 to 2021-06-30$87.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2021-01-01 to 2021-06-30$170.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2021-04-01 to 2021-06-30$21.9mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2021-01-01 to 2021-06-30$44.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-04-01 to 2021-06-30$14.8mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2021-01-01 to 2021-06-30$26.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-04-01 to 2021-06-30−$3.1mus-gaap:OperatingIncomeLoss
Operating income6 months2021-01-01 to 2021-06-30$8.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-04-01 to 2021-06-30$6.7mus-gaap:InterestExpense
Interest expense6 months2021-01-01 to 2021-06-30$13.7mus-gaap:InterestExpense
Income tax3 months2021-04-01 to 2021-06-30$21.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2021-01-01 to 2021-06-30$1.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-04-01 to 2021-06-30$1.6mus-gaap:NetIncomeLoss
Net income6 months2021-01-01 to 2021-06-30$7.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-04-01 to 2021-06-30$0.05us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2021-01-01 to 2021-06-30$0.23us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-04-01 to 2021-06-30$0.05us-gaap:EarningsPerShareBasic
Basic EPS6 months2021-01-01 to 2021-06-30$0.23us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-04-01 to 2021-06-3031,189,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2021-01-01 to 2021-06-3031,192,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2021-01-01 to 2021-06-30−$37.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2021-01-01 to 2021-06-30$937.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid6 months2021-01-01 to 2021-06-30$21.5mus-gaap:PaymentsOfDividends
Share repurchases6 months2021-01-01 to 2021-06-30$11.1mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-06-30$410.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-06-30$922.7mus-gaap:AssetsCurrent
Total assetsAt period end2021-06-30$1.50bnus-gaap:Assets
Current liabilitiesAt period end2021-06-30$234.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-06-30$780.8mus-gaap:Liabilities
Long-term debtAt period end2021-06-30$420.6mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2021-06-30$704.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001405495-21-000036. Last ingested by Listed: Nov 6, 2026, 12:17 ET. Listed shows no prices and gives no investment advice.